Heterogeneity of c-Met expression in Chinese gastric cancer patients

Human Pathology

Volumn 46, Issue 12, 2015, Pages 1901-1907

  Zhu, Chunchao ^a   Xu, Jia ^a   Li, Maoran ^a   Zhao, Gang ^a   Cao, Hui ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Amplification; c Met; Gastric cancer; Heterogeneity; Homogeneity; Overexpression

Indexed keywords

SCATTER FACTOR RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CHINESE; CLINICAL ARTICLE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTRECTOMY; GENE AMPLIFICATION; GENE DOSAGE; GENE OVEREXPRESSION; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; STOMACH CANCER; ASIAN CONTINENTAL ANCESTRY GROUP; BIOSYNTHESIS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; STOMACH TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BIOMARKERS, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-MET; STOMACH NEOPLASMS;

EID: 84947266434     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2015.06.025     Document Type: Article

References (34)

1. G. Cooper, M. Park, D. Blair, and et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line Nature 311 1984 29 33
2. Y. Chua, and D. Cunningham The UK NCRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer: implications for clinical practice Ann Surg Oncol 14 2007 2687 2690
3. W. Koizumi, H. Narahara, T. Hara, and et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9 2008 215 221
4. N. Boku, S. Yamamoto, H. Fukuda, and et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study Lancet Oncol 10 2009 1063 1069
5. Y. Bang, E.V. Cutsem, A. Feyereislova, and et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 2010 687 697
6. K. Fujimoto-Ouchi, H. Yasuno, Y. Moriya, K. Mori, and Y. Tanaka Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models Cancer Chemother Pharmacol 59 2007 795 805
7. A. Nagatsuma, M. Aizawa, T. Kuwata, and et al. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma Gastric Cancer 18 2015 227 238
8. S. Lim, J. Lim, and J.Y. Cho Targeted therapy in gastric cancer: personalizing cancer treatment based on patient genome World J Gastroenterol 28 2014 2042 2050
9. Y. Zhang, and G.V. Woude HGF/SF-met signaling in the control of branching morphogenesis and invasion J Cell Biochem 88 2003 408 417
10. S. Corso, P. Comoglio, and S. Giordano Cancer therapy: can the challenge be MET? Trends Mol Med 11 2005 284 292
11. T. Nakamura, S. Mizuno, K. Matsumoto, Y. Sawa, H. Matsuda, and T. Nakamura Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF J Clin Invest 106 2000 1511 1519
12. C. Huh, V. Factor, A. Sánchez, K. Uchida, E.A. Conner, and S.S. Thorgeirsson Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair Proc Natl Acad Sci U S A 101 2004 4477 4482
13. C. Migliore, and S. Giordano Molecular cancer therapy: can our expectation be MET? Eur J Cancer 44 2008 641 651
14. F. Maina, G. Panté, F. Helmbacher, and et al. Coupling Met to specific pathways results in distinct developmental outcomes Mol Cell 7 2001 1293 1306
15. B. Peruzzi, and D. Bottaro Targeting the c-Met signaling pathway in cancer Clin Cancer Res 12 2006 3657 3660
16. J. Lee, J. Seo, H.J. Jun, and et al. Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target Oncol Rep 25 2011 1517 1524
17. Z. Peng, Y. Zhu, Q. Wang, and et al. Prognostic significance of MET amplification and expression in gastric cancer: a systematic review with meta-analysis PLoS One 9 2014 e84502
18. D. Tulasne, and B. Foveau The shadow of death on the MET tyrosine kinase receptor Cell Death Differ 15 2008 427 434
19. K. Tsugawa, Y. Yonemura, Y. Hirono, and et al. Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features Oncology 55 1998 475 481
20. T. Hara, A. Ooi, M. Kobayashi, M. Mai, K. Yanagihara, and I. Nakanishi Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization Lab Invest 78 1998 1143 1153
21. C. Gao, and Y. Lu Correlation of multiple gene changes with malignant phenotype of human gastric carcinoma Zhonghua Yi Xue Za Zhi 76 1996 671 675
22. Y. Liu, D. Shen, X. Yin, and et al. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma Br J Cancer 110 2014 1169 1178
23. R. Salgia, P. Patel, J. Bothos, and et al. Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies Clin Cancer Res 20 2014 1666 1675
24. K. Oliner, R. Tang, A. Anderson, and et al. Evaluation of Met pathway biomarkers in a phase II study of rilotumumab (R, AMG102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer J Clin Oncol 30 2012 abstract 4005
25. S. Hong, P. LoRusso, O. Hamid, and et al. First-in-human study of AMG 337, a highly selective oral inhibitor of MET, in adult patients (pts) with advanced solid tumors J Clin Oncol 32 5 Suppl. 2014 [abstract 508]
26. R. Fisher, L. Pusztai, and C. Swanto Cancer heterogeneity: implications for targeted therapeutics Br J Cancer 108 2013 479 485
27. A. Wolff, M. Hammond, J. Schwartz, and et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 2007 118 145
28. N. McGranahan, R. Burrell, D. Endesfelder, M.R. Novelli, and C. Swanton Cancer chromosomal instability: therapeutic and diagnostic challenges EMBO Rep 13 2012 528 538
29. D. Sidransky, T. Mikkelsen, K. Schwechheimer, M.L. Rosenblum, W. Cavanee, and B. Vogelstein Clonal expansion of p53 mutant cells is associated with brain tumour progression Nature 355 1992 846 847
30. S. Shah, R. Morin, J. Khattra, and et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution Nature 461 2009 809 813
31. P. Campbell, S. Yachida, L.J. Mudie, and et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer Nature 467 2010 1109 1113
32. L. Ding, T. Ley, D.E. Larson, and et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing Nature 481 2012 506 510
33. R. Tajiri, A. Ooi, T. Fujimura, and et al. Intratumoral heterogeneous amplification of ERBB2 and subclonal genetic diversity in gastric cancers revealed by multiple ligation-dependent probe amplification and fluorescence in situ hybridization Hum Pathol 45 2014 725 734
34. H. Grabsch, S. Sivakumar, S. Gray, H.E. Gabbert, and W. Müller HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value: conclusions from 924 cases of two independent series Cell Oncol 32 2010 57 65